Monitor the special stockholder meeting vote and regulatory approvals for the merger and asset sales. The CVR structure provides potential upside from legacy business monetization, but payments are uncertain. The combined company's success hinges on Treeline's clinical pipeline progress.
Price Chart
Executive Summary
Standard BioTools filed Amendment No. 2 to its S-4 registration statement for the all-stock merger with Treeline Biosciences. The merger values Treeline at $2.5 billion and Standard BioTools at $460 million, with former Standard BioTools stockholders expected to hold ~16% of the combined company. The filing also covers the $5.5 million sale of Standard BioTools' mass cytometry business to Element Biosystems and the issuance of CVRs to Standard BioTools stockholders. The merger is expected to close in Q4 2026, subject to stockholder and regulatory approvals.
Key Facts
- Standard BioTools and Treeline entered into an all-stock merger with Treeline valued at $2.5 billion and Standard BioTools at $460 million.
- Former Standard BioTools stockholders will hold ~16% of the combined company; former Treeline stockholders will hold ~84%.
- Standard BioTools is selling its mass cytometry business to Element Biosystems for $5.5 million and its microfluidics business to ARCHIMED.
- Standard BioTools stockholders will receive one CVR per share, entitling them to a pro-rata share of net proceeds from the sale of legacy businesses over five years, capped at 76 million shares.
- The combined company will be renamed Treeline Biosciences, Inc. and trade under the symbol TRLN.
- A reverse stock split of 1-for-20 to 1-for-40 is proposed to meet Nasdaq listing requirements.
- Treeline is a clinical-stage biopharma with four Phase 1 programs (TLN-121, TLN-254, TLN-372, TLN-499) in oncology.
- The merger is expected to close in Q4 2026, subject to stockholder and regulatory approvals.
Financial Impact
Treeline valued at $2.5 billion; Standard BioTools at $460 million; mass cytometry business sold for $5.5 million; combined company pro forma cash of ~$1.03 billion as of June 30, 2026.
Risk Factors
- Merger may not close if stockholder or regulatory approvals are not obtained.
- Standard BioTools stockholders face significant dilution, owning only ~16% of the combined company.
- Treeline is a pre-revenue clinical-stage company with no approved products and a history of net losses.
- CVR payments are contingent and may be zero.
- The reverse stock split may not sustain the stock price above Nasdaq's minimum bid requirement.
Investment Themes
Documents Analyzed
This report is based on 13 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001140361-26-039290 |
| Document: ny20077604x5_ex10-9.htm | 0001140361-26-039290 |
| Document: ny20077604x5_ex10-6.htm | 0001140361-26-039290 |
| Document: ny20077604x5_ex10-7.htm | 0001140361-26-039290 |
| Document: ny20077604x5_ex10-8.htm | 0001140361-26-039290 |
| Document: ny20077604x5_ex5-1.htm | 0001140361-26-039290 |
| Document: ny20077604x5_ex99-1.htm | 0001140361-26-039290 |
| Document: ny20077604x5_ex99-2.htm | 0001140361-26-039290 |
| Document: ny20077604x5_ex23-2.htm | 0001140361-26-039290 |
| Document: ny20077604x5_ex23-3.htm | 0001140361-26-039290 |
| Document: 0001140361-26-039290-index-headers.html | 0001140361-26-039290 |
| Document: 0001140361-26-039290-index.html | 0001140361-26-039290 |
| Document: 0001140361-26-039290.txt | 0001140361-26-039290 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | EFFECT | $0.6400 $0.6056 | ▼ −5.38% | ▼ −4.85% | $0.6200 (−3.12%) |
Oct 21, 2026 6d ago | S-4/A | $0.6500 $0.6400 | ▲ +1.54% | ▲ +0.36% | $0.6200 (+4.62%) |
Oct 9, 2026 18d ago | S-4/A | $0.6578 $0.6589 | ▲ +0.17% | ▲ +0.18% | $0.6200 (−5.75%) |
Oct 5, 2026 22d ago | 425 | $0.7220 $0.6787 | ▼ −6.00% | ▼ −5.76% | $0.6200 (−14.13%) |
Oct 5, 2026 22d ago | 8-K | $0.7220 $0.6787 | ▼ −6.00% | ▼ −5.76% | $0.6200 (−14.13%) |
Oct 5, 2026 22d ago | Press Release | $0.7220 $0.6787 | ▼ −6.00% | ▼ −5.76% | $0.6200 (−14.13%) |
Sep 30, 2026 27d ago | 425 | $0.7283 $0.7447 | ▲ +2.25% | ▲ +1.51% | $0.6200 (−14.87%) |
Sep 30, 2026 27d ago | 8-K | $0.7283 $0.7447 | ▲ +2.25% | ▲ +1.51% | $0.6200 (−14.87%) |
Jul 29, 2026 12w ago | 425 | $0.8739 $0.8973 | ▲ +2.68% | ▲ +1.00% | $0.6200 (−29.05%) |
Jul 28, 2026 13w ago | Press Release | $0.7947 $0.8739 | ▲ +9.97% | ▲ +11.50% | $0.6200 (−21.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers